Peptide Safety: Contraindications, Side Effects, and What to Avoid

Some exclusions apply to essentially the entire peptide database. If any of the following apply, the research answer is not "pick a safer peptide" — it is "no peptide protocol":

• •Pregnancy or breastfeeding: every category includes peptides that affect hormones, blood vessels, or fetal development; all research protocols exclude it.
• •Active cancer, or a significant undiagnosed mass: growth-factor, angiogenesis, and hormone-signaling peptides can support tumor biology. Recovery and anti-aging categories are the clearest cases, but the caution is universal.
• •Active severe infection (for immune-modulating categories): stimulating an immune system that is mid-battle can worsen the outcome rather than help.
• •History of severe allergic reactions or anaphylaxis to peptide products.
• •Under 18: growth-axis and hormonal peptides are excluded outright; everything else lacks any safety data for minors.

The protocol engine on this site screens every peptide against this exact class of data before recommending anything — but the engine is a research tool, not a doctor. Your provider needs to see the list.

• •Insulin: GLP-1 agonists and GH secretagogues both alter glucose handling. Stacking with exogenous insulin is a hypoglycemia risk — professional supervision only.
• •Warfarin and anticoagulants: BPC-157 and the recovery category interact with bleeding control. Any anticoagulant requires prescriber involvement.
• •SSRIs / MAOIs: tesofensine, PE-22-28, and several cognitive peptides modulate serotonin or monoamine systems — combining them with serotonergic drugs risks serotonin syndrome or destabilization.
• •Immunosuppressants: immune-modulating peptides (thymosin alpha-1, thymalin, LL-37) can oppose the entire purpose of the immunosuppressant.
• •Thyroid medication: GH-releasing peptides alter thyroid conversion; thyroid disorders need to be controlled first.
• •Blood pressure medication: melanocortins (PT-141, MT-II) and VIP raise/lower pressure in opposite but unpredictable directions when combined with antihypertensives.

Across categories, in order of how often they actually occur in research and community reports:

• •Injection-site reactions (redness, irritation, bruising) — the most common by far, mostly technique and rotation dependent.
• •Nausea / GI effects — dominant in the GLP-1 family; titration-dependent.
• •Water retention, flushing, tingling — GH secretagogue signatures.
• •Hunger increase — GHRP-6 specifically (feature or bug, depending on your goal).
• •Headache, transient fatigue, dizziness — scattered across categories.
• •Hypoglycemia risk — IGF-1 LR3 and glucose-modulating peptides.

• •Severe, persistent abdominal pain (GLP-1 pancreatitis signal — emergency evaluation, do not wait)
• •Chest pain, palpitations, or fainting (melanocortins, CNS-active peptides)
• •Facial swelling, hives, difficulty breathing (anaphylaxis — emergency)
• •Severe hypoglycemia symptoms: confusion, sweating, shakiness (IGF-1, insulin-adjacent protocols)
• •Unusual mood changes, mania, or psychiatric destabilization (cognitive category)
• •Persistent pain at an injection site with spreading redness (infection — needs medical review)

Most "peptide side effects" reported anecdotally trace back to material quality, not the peptide molecule. Research-grade peptides vary enormously:

• •Third-party COA: certificates of analysis from an independent lab verifying identity and purity. No COA, no protocol — full stop.
• •Purity thresholds: research standard is ≥98–99% by HPLC; below that, the impurities are the side effects.
• •Endotoxin testing: bacterial endotoxin contamination causes flu-like reactions that get blamed on the peptide.
• •Storage chain: peptides degrade with heat and light. A great peptide shipped in a hot warehouse for two weeks is not a great peptide anymore.
• •Price sanity: peptide synthesis has real costs. Deals 3–4x below market usually mean underdosed, contaminated, or entirely different compounds — several "BPC-157" samples have tested as filler only.

• •Start at the low end of every range, always — no exceptions for experience level.
• •One new peptide at a time; never change two variables in the same week.
• •Keep a log: peptide, lot number, dose, time, how you felt. Patterns invisible day-to-day are obvious on paper.
• •Titrate on schedule, not on impatience — the GLP-1 timeline guide covers why skipping steps backfires.
• •Respect the cycle and break structure; unbroken multi-month runs are how mild peptides become problem peptides.